A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer
Immunotherapeutic survivin vaccine DPX-Survivac, low dose oral cyclophosphamide, and IDO1
inhibitor epacadostat will be tested together for the first time in patients with recurrent
ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential
immune-modulating activity of the combination of these agents.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society